Skybiotech Healthcare Limited Reports FY26 Audited Results

Skybiotech Healthcare Limited reported its audited financial results for the year ended March 31, 2026, with consolidated revenue at ₹7.10 crore and a consolidated net loss of ₹-1.12 crore.

Reader Takeaway: Loss reduction in consolidated results; ongoing operational cash burn.

What just happened

Skybiotech Healthcare Limited (formerly Kapil Cotex Limited) has announced its audited financial results for the fiscal year 2026. The company reported consolidated revenue of ₹7.10 crore, a slight increase from ₹7.05 crore in the previous fiscal year. However, the consolidated net loss for the period narrowed to ₹-1.12 crore, down from ₹-2.37 crore in FY25. The auditor has provided an unmodified opinion on these results.

Why this matters

The results reflect the company's ongoing transition from its previous textile business towards the healthcare and biotechnology sector, signaled by its name change to Skybiotech Healthcare Limited, effective November 7, 2025. While the reduction in net loss is a positive sign, the company continues to operate at a loss and shows negative cash flow from operations.

The backstory

Skybiotech Healthcare Limited was formerly known as Kapil Cotex Limited. The strategic pivot to the healthcare sector marks a significant change in its business direction. The subsidiary, Skybiotech Life Sciences Private Limited, is central to this new focus, contributing most of the consolidated operational figures.

What changes now

Investors will be watching how effectively Skybiotech Healthcare establishes itself in the new sector. The results show that while losses have decreased, the company is still burning cash from operations, with a consolidated negative cash flow from operating activities of ₹-1.52 crore for FY26. The performance of the subsidiary is crucial for the group's future success.

Risks to watch

The primary risks include continued operational losses on both standalone and consolidated levels, and persistent negative operating cash flows, which indicate liquidity challenges. The success of the new healthcare venture is yet to be proven.

Peer comparison

As the company is in a transition phase and pivoting to a new sector, direct peer comparison based on current financials might be challenging. Its previous identity as a textile company is no longer representative of its future strategy.

Context metrics (time-bound)

For the year ended March 31, 2026:

• Consolidated Revenue: ₹7.10 crore
• Consolidated Net Loss: ₹-1.12 crore
• Standalone Total Income: ₹0.067 crore
• Standalone Net Loss: ₹-0.06 crore
• Consolidated Negative Operating Cash Flow: ₹-1.52 crore

What to track next

Investors should closely monitor the company's progress in the healthcare sector, its ability to achieve profitability, and improvements in operational cash flow in the upcoming financial periods. The performance of its subsidiary, Skybiotech Life Sciences, will be a key indicator.